Cytomegalovirus (CMV) Diagnostic Market Size, Share, Growth, Trends, and Global Industry Analysis: By Sample Extract (Urine, and Blood), By Drug Type (Valganciclovir, Ganciclovir, Cidofovir, Foscarnet, and Others), By Test Type (Serology, Cell Culture, Antigenemia, Polymerase Chain Reaction Amplification, Immunohistochemistry, Nucleic Acid Sequence Based Amplification (NASBA), and Hybrid Capture Assay), By Application Type (Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others (Mouth Ulcers, Pharyngitis, etc.), By End User (Hospitals, Diagnostic Centers, Clinics, and Others), and Region

Cytomegalovirus Diagnostics Market size was valued at US$ 73.6 million in 2023 and is poised to grow at a significant CAGR of 6.1% from 2024-2030. The global cytomegalovirus (CMV) diagnostic market held a significant market share during the estimated period. CMV is a common virus that causes serious complications, especially in individuals having weak immune systems who have AIDS/HIV, newborns, and organ transplant recipients. The main drivers for the market growth are huge investments in research and development by the players, the introduction of novel medicines, and the rise in cases of cytomegalovirus infections. According to the National Library of Medicine report of August 2023, 60% to 70% of adults get infected by CMV in developed countries and almost 100% in developing countries which is the driving dynamic for the CMV diagnostic market. The market for CMV treatments is vulnerable to falling transplant rates and decreasing CMV prevalence carried on by highly active antiretroviral therapy (HAART). However, alternatives such as Cryotherapy and laser therapy compete for market share.

The Cytomegalovirus Diagnostics Market Key Developments:

• In September 2022, ProBioGen agreed with the City of Hope to manufacture the CMV vaccine for clinical trials and commercial distribution which helped the company accelerate the development and production of the CMV vaccine which could save many lives.
• In November 2021, the US Food and Drug Administration (FDA) approved maribavir, the Takeda pharmaceuticals product that can treat pediatric patients of 12 years of age, adults, and also the elderly with post-transplant. Cytomegalovirus infection is refractory to treatment with ganciclovir, cidofovir, valganciclovir, or foscarnet. The FDA’s approval has strengthened the overall company’s market position.